Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 9/20 | 0.57 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.45 |
| ▸ | CNR1 | P21554 | 3/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1993275 | 0.94 | CYP19A1 (0.58) | CYP19A1CREBBPLMNACAMK2DCNR1 | |
| SCHEMBL29324305 | 0.84 | CNR1 (0.48) | CREBBPLMNACAMK2DCNR1CNR2 | |
| SCHEMBL14333263 | 0.82 | CNR1 (0.58) | CYP19A1CREBBPLMNACAMK2DCNR1 | |
| SCHEMBL9354163 | 0.80 | CAMK2D (0.49) | LMNACAMK2DCNR1CNR2NR4A2 | |
| SCHEMBL29324307 | 0.80 | LMNA (0.53) | LMNACAMK2DCNR2 | |
| SCHEMBL29443972 | 0.78 | MAPT (0.45) | CREBBPLMNACAMK2DL3MBTL1 | |
| SCHEMBL2033409 | 0.77 | CNR2 (0.60) | CYP19A1CREBBPLMNACNR1CNR2 | |
| SCHEMBL14486724 | 0.76 | CAMK2D (0.54) | CAMK2DCNR1CNR2NR4A2 | |
| SCHEMBL1995045 | 0.76 | CYP19A1 (0.51) | CYP19A1CREBBPLMNACNR1 | |
| SCHEMBL28840703 | 0.76 | CNR1 (0.69) | CYP19A1CREBBPLMNACNR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9364459-B2 | 3-(indolyl)- or 3-(azaindolyl)- 4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma | Johannes Gutenberg-Universität Mainz (DE) | 2016-06-14 | — | — | US | disclosed |
| EP-2512469-B1 | 3-(INDOLYL)-OR 3-(AZAINDOLYL)- 4-ARYLMALEIMIDE DERIVATIVES FOR USE IN THE TREATMENT OF COLON AND GASTRIC ADENOCARZINOMA | JOHANNES GUTENBERG UNIVERSITÄT MAINZ (DE) | 2016-03-02 | — | — | EP | disclosed |
| EP-2513089-B1 | 3-(INDOLYL)- OR 3-(AZAINDOLYL)-4-ARYLMALEIMIDE COMPOUNDS AND THEIR USE IN TUMOR TREATMENT | JOHANNES GUTENBERG UNIVERSITÄT MAINZ (DE) | 2015-09-09 | — | — | EP | disclosed |
| US-9012659-B2 | 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment | Johannes Gutenberg—Universitat Mainz (DE) | 2015-04-21 | — | — | US | disclosed |
| US-20130131060-A1 | 3-(INDOLYL)- OR 3-(AZAINDOLYL)- 4-ARYLMALEIMIDE COMPOUNDS AND THEIR USE IN TUMOR TREATMENT | Johannes Gutenberg-Universität Mainz (DE) | 2013-05-23 | — | — | US | disclosed |
| US-20130029986-A1 | 3-(INDOLYL)- OR 3-(AZAINDOLYL)- 4-ARYLMALEIMIDE DERIVATIVES FOR USE IN THE TREATMENT OF COLON AND GASTRIC ADENOCARZINOMA | UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ (DE) | 2013-01-31 | — | — | US | disclosed |
| EP-2343291-A1 | 3-(Indolyl)- or 3-(Azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment | Johannes Gutenberg-Universität Mainz (DE) | 2011-07-13 | — | — | EP | disclosed |
| EP-2338486-A1 | 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma | Johannes Gutenberg-Universität Mainz (DE) | 2011-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029986-A1 | 3-(INDOLYL)- OR 3-(AZAINDOLYL)- 4-ARYLMALEIMIDE DERIVATIVES FOR USE IN THE TREATMENT OF COLON AND GASTRIC ADENOCARZINOMA | SI, AADAC, INMT | CYP19A1 643/4885CREBBP 3376/4885LMNA 3284/4885 |
| US-20130131060-A1 | 3-(INDOLYL)- OR 3-(AZAINDOLYL)- 4-ARYLMALEIMIDE COMPOUNDS AND THEIR USE IN TUMOR TREATMENT | IDH3A, INMT, IDH1 | CYP19A1 350/4885CREBBP 3320/4885LMNA 3123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.